{
  "id": 20288110,
  "title": "Cytokinetics stock hits 52-week low at $53.53",
  "url": "https://urgent.news/2026/11/16/cytokinetics-stock-hits-52-week-low-at-53-53",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-16T15:04:16.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/cytokinetics-stock-hits-52week-low-at-5353-93CH-5030359"
  },
  "original_language": "en",
  "account": "Cytokinetics Inc's stock recently dipped to a 52-week low of $53.53, just above its 52-week low of $53.55, marking a 39% decrease from its 52-week high of $88.31. The biopharmaceutical company experienced a challenging year, with shares declining by about 15.5% over the past year. According to InvestingPro analysis, the stock may be undervalued, placing it among the most undervalued stocks available. The decline to this new low reflects the market's sentiment towards the company's financial performance and future prospects. However, there are positive indicators: analysts predict sales growth for the current year, with a significant 30% revenue growth over the last year. Investors are keenly observing any strategic moves that could impact the stock's performance in the future. Cytokinetics Inc. also reported third-quarter 2026 financial results that exceeded Wall Street expectations, driven by strong sales of its heart drug MYQORZO. The company reported an adjusted loss of $1.37 per share, narrower than the expected loss of $1.45 per share. Revenue for the quarter reached $47.6 million, surpassing the forecasted $40.61 million. These results indicate stronger-than-expected performance in MYQORZO sales, contributing to the positive financial outcome. Despite the narrower loss, Cytokinetics continues to face substantial spending and losses, which investors are closely monitoring. Recent financial developments have caught the attention of various analyst firms, though no specific upgrades or downgrades have been disclosed. Investors and analysts remain vigilant as Cytokinetics navigates its financial challenges.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}